PSYENCE BIOMEDICAL LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.329 USD | -7.53% |
|
-15.64% | -96.44% |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 132M |
|---|---|---|---|---|---|
| Net income 2022 | -2M | Net income 2023 | -4M | EV / Sales 2022 | - |
| Net cash position 2022 | 2.19M | Net cash position 2023 | 1.81M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-
| Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 23.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -7.53% | ||
| 1 week | -15.64% | ||
| Current month | -56.13% | ||
| 1 month | -59.03% | ||
| 3 months | -71.14% | ||
| 6 months | -96.34% | ||
| Current year | -96.44% |
1 week
0.27
0.41
1 month
0.270.79
Current year
0.2712.60
1 year
0.2714.55
3 years
0.2714.55
5 years
0.2714.55
10 years
0.2714.55
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 0.3 | -8.81% | 361,707 |
| 24-06-27 | 0.329 | -7.53% | 550,205 |
| 24-06-26 | 0.3558 | -3.26% | 300,588 |
| 24-06-25 | 0.3678 | -1.00% | 287,543 |
| 24-06-24 | 0.3715 | -4.74% | 990,289 |
End-of-day quote Nasdaq, June 26, 2024
More quotes
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Companyâs clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -96.44% | 4.02M | |
| +55.32% | 815B | |
| +44.05% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- PBM Stock
